Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease

Inclusion Criteria: * Male or female age 18 to 50 (inclusive) years old at the time of enrollment * Have negative anti-dengue, Japanese encephalitis, West Nile, and yellow fever ELISA serological tests * Be informed of the nature of the study and provide written informed consent * If the subject is of child-producing potential, he/she agrees to practice adequate birth control or abstain from sex * Have access to the WRAIR Clinical Trials for at least 270 days, and be willing to refrain from participation in other investigational clinical trials * Be in good general health Exclusion Criteria-Subjects meeting any of the following criteria will be excluded from the study: * History of Flavivirus infection or history of Flavivirus vaccine (experimental or licensed product) including Japanese encephalitis, yellow fever, and dengue * Have a known or suspected hypersensitivity or adverse reaction to vaccines including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain * Have received a live-attenuated vaccine within 42 days prior to the initial injection on Day 0 or a subunit or killed vaccine within 30 days of the initial injection on Day 0 * Have a positive screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or HIV antibody * Are pregnant or breastfeeding * Have donated or received blood, blood products, or plasma within 30 days prior to Day 0 * Have any acute illness, including an oral body temperature \>100.4°F, within 7 days before the initial injection on Day 0 * Have a past or current history of malignant disease except for adequately treated skin cancer * Exclusions include but are not limited to conditions pertaining to or evidence of immunodeficiency; allergies requiring treatment with antigen injections; autoimmune disease; severe migraine headaches; unstable asthma; clinically significant cardiac arrhythmias, diabetes mellitus, thyroid disease, a bleeding disorder or a seizure disorder. * Have participated in an investigational drug, vaccine, or device study within a period of 30 days prior to Day 0; * History of splenectomy * Planned travel to dengue endemic areas during the study period